Blog des AK Psychiatriekritik der NFJ Berlin

Yes, the Tide is Turning Against Psychiatry

The suggestion embedded in this article’s title seems counter-intuitive. How could the tide be turning on psychiatry when the institution has never been so strong? And indeed indicators of its growing strength and tenacity are all around us. The exporting of its model to the global south via the World Bank, the emergence of outpatient committal, the explosion of funding for psychiatric research (see Burstow, 2015). Correspondingly, daily are there calls for most aggressive “detection” and “treatment”  (e.g., Jeffrey Lieberman, 2015). And the mainstream press has never been more closed to truly foundational critiques. That acknowledged, let me suggest that such intensification is common when an old system is in the early days of crumbling.

Of course, intensification itself is hardly an indicator that a reversal is at hand. So how would we know? Examples of possible indicators are: Ever growing critiques from inside and outside the profession, growing discomfort with “anomalies” (in essence, the indicators of a paradigm shift spelt out by Kuhn, 1962). Established moral authorities making unprecedented negative pronouncements about the current state of affairs. The surfacing of more and more tales of corruption and fraud. The rising up of those subjected to it. Each of these signs and more we are experiencing now with psychiatry — hardly conclusive individually, but taken together, convincing portents of a societal shift.


The Divided Laing, Arcola Theatre

New RD Laing drama is a surreal tribute to a great 20th-century thinker and radical

RD (“Ronnie”) Laing was a typically eccentric 1960s guru. A Scottish psychiatrist who was one of the leading lights of the anti-psychiatry movement, his 1960 classic The Divided Self helped a whole generation to a deeper understanding of mental illness and especially the experience of psychosis. This new drama, by theatre writer and critic Patrick Marmion, is an exploration of an imaginary episode in his life, and is staged on the occasion of the 50th anniversary of the Philadelphia Association, a therapeutic collective which Laing co-founded, and of his experimental asylum at Kingsley Hall in London’s Bromley-by-Bow.


Crisis is (un)Learning

The mission statement for the Western Mass Recovery Learning Community’s (RLC) peer respite (Afiya) is:

“To provide a safe space in which each person can find the balance and support needed to turn what is so often referred to as ‘crisis’ into a learning and growth opportunity.”

Although I sometimes question our choice to use the word ‘safe’ (given how impossible an absolute version of ‘safe’ is to achieve and how saddled with distasteful meaning such a term can be within the mental health system), I’m not sure that statement could otherwise be any more straight forward and meaningful. Yet, so often, It’s unclear what meaning people are truly making of it.


My Response To Dr. Pies

In the October 2015 issue of The Behavior Therapist (pages 206-213), Jeffrey Lacasse, PhD, and Jonathan Leo, PhD, published an article titled Antidepressants and the Chemical Imbalance Theory of Depression: A Reflection and Update on the Discourse.

I thought the article had particular merit, and I drew attention to it in a post dated November 2.  The post, More on the Chemical Imbalance Theory, was also published on Mad in America.

In that post, I quoted a number of passages from the Behavior Therapist article, including:


Medication Mechanization: Microchip Sensors in Abilify to Increase Medication Compliance

I felt a chill go through my body when I read that the FDA has agreed to review for possible approval in early 2016 a new form of the drug Abilify that contains a microchip sensor capable of sending a message that indicates the exact time a tablet dissolves in the stomach. The message is recorded by a skin patch – along with data such as the person’s body angle and activity patterns – and, according to a press release from Proteus Digital Health, the developer of the device, “this information is recorded and relayed to patients on a mobile phone or other Bluetooth-enabled device, and only with their consent, to their physician and/or their caregivers.”

The Japanese drug giant Otsuka teamed up with Proteus Digital Health in 2012 to create this potentially profitable new “chip in a pill” just as its patent on Abilify – at $6.9 billion the #1 most profitable drug in the U.S. in 2013 – was set to expire in 2014, leaving one of Otsuka’s most valuable markets vulnerable to generics. It is especially ominous to me that our government is teetering toward passing the Murphy Bill, which would make forced in-home treatment the law of the land, at the same time it is lurching toward putting such an Orwellian device in the hands of a pharmaceutical company, courts, and families.



Erhalte jeden neuen Beitrag in deinen Posteingang.

Schließe dich 30 Followern an